IRD
NASDAQ · Biotechnology
Opus Genetics Inc
$3.64
-0.08 (-2.15%)
Open$3.75
Previous Close$3.72
Day High$3.76
Day Low$3.60
52W High$5.81
52W Low$1.04
Volume—
Avg Volume802.9K
Market Cap309.49M
P/E Ratio—
EPS$-1.32
SectorBiotechnology
Analyst Ratings
Strong Buy
23 analysts
Price Target
+537.6% upside
Current
$3.64
$3.64
Target
$23.21
$23.21
$16.63
$23.21 avg
$31.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 19.40M | 27.37M | 29.63M |
| Net Income | -67,764,368 | -86,031,783 | -1,185,756 |
| Profit Margin | -349.3% | -331.9% | -4.0% |
| EBITDA | -52,672,555 | -70,586,722 | -1,569,658 |
| Free Cash Flow | — | — | -1,455,645 |
| Rev Growth | -29.1% | -29.1% | +20.7% |
| Debt/Equity | 0.07 | 0.07 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |